Trials / Completed
CompletedNCT00609921
A Phase 1 Study of ARQ 197 in Patients With Solid Tumors
A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients With Advanced/Recurrent Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, open label, dose escalation study of ARQ 197 in patients with advanced/recurrent solid tumors. The purpose of this study is to determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARQ197 | treatment |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2011-09-01
- First posted
- 2008-02-07
- Last updated
- 2012-09-07
Source: ClinicalTrials.gov record NCT00609921. Inclusion in this directory is not an endorsement.